Form 4: Replimune Director Dieter Weinand Granted 44,500 Options

Replimune Group, Inc. director Dieter Weinand received a grant of 44,500 stock options with an exercise price of $7.61, vesting in full in April 2027.

Summary

• Director Dieter Weinand was granted 44,500 stock options on April 1, 2026.
• The options carry an exercise price of $7.61 per share.
• The grant is scheduled to vest in its entirety on April 1, 2027.
• The options have a ten-year term, expiring on April 1, 2036.
• The filing was submitted on April 7, 2026, which was noted as a late filing due to administrative error.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive administrative filing, as it confirms continued insider alignment despite the minor reporting delay.

Positives

• Aligns director interests with shareholders through equity-based compensation.
• The 10-year expiration date suggests a long-term commitment to the company's growth.
• The exercise price of $7.61 sets a clear benchmark for value creation.

Negatives

• The filing was submitted late, which indicates a minor lapse in administrative compliance procedures.

Risks

• The options only provide value if the market price of REPL exceeds $7.61 after the vesting date.
• Potential for future dilution of existing shareholders upon exercise of these options.

Future Outlook

The grant indicates that the board member remains incentivized to oversee the company's strategic direction through at least the vesting period in 2027.

Management Comments

• This Form 4 is being filed late due to inadvertent administrative error.

Industry Context

StockSavvy.ai notes that equity grants are a standard component of director compensation in the biotechnology sector, used to preserve cash while ensuring board members are focused on long-term share price appreciation.

Comparison to Industry Standards

• The grant size of 44,500 options is consistent with mid-cap biotech board compensation packages.
• A one-year cliff vesting schedule is a common practice for annual director equity awards in the NASDAQ Biotechnology Index.

Related Party Transactions

• Grant of 44,500 stock options to Director Dieter Weinand as part of standard compensation.

Stakeholder Impact

• Shareholders: Interests are aligned with the director, though minor dilution may occur in the future.
• Management: Administrative processes for SEC filings may require review to prevent future late submissions.

Next Steps

• Vesting of the 44,500 options on April 1, 2027.

Key Dates

Recommendation

This is a routine compensation-related filing that does not change the fundamental valuation of the company, though it confirms the director's continued involvement.

Keywords

Replimune Group, REPL, Stock Options, Insider Trading, Dieter Weinand, Director Compensation, Biotechnology